<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012725/" ref="ordinalpos=620&amp;ncbi_uid=6121171&amp;link_uid=PMC4012725" image-link="/pmc/articles/PMC4012725/figure/F1/" class="imagepopup">Figure 1. Targeting synergistic dependency on MAPK and dopamine <span class="highlight" style="background-color:">signaling</span> in glioblastoma.  From: Dopamine <span class="highlight" style="background-color:">signaling</span>: target in glioblastoma. </a></div><br /><div class="p4l_captionBody">Canonical pro-survival and mitogenic MAPK signaling, commonly deregulated in glioblastoma, is depicted as a simplified signaling cascade of EGFR, Ras-GTP and MAPK kinases Erk1 and Erk2 (Erk1/2). At the Ras node, MAPK pathway is positively modulated by dopamine signaling. Upon ligand binding, the DRD2 receptor holds inactive small GTPase Rap1 through activation of heterotrimeric G protein alpha i2 (alpha/beta/gamma) and the GTPase-activating protein RAP (RAP-GAPII), which promote GDP-bound (inactive) Rap1. Rap1 is a Ras antagonist and its inactivation thus results in amplification of MAPK signaling. Therefore, combined targeting of both pathways can offer a promising strategy for glioblastoma therapy.</div></div>